Cristina Rodriguez-Antona

List of Publications by Year
in descending order

142 papers	8,574 citations	53794 45 h-index	60623 81 g-index
145 all docs	145 docs citations	145 times ranked	12752 citing authors

#	Article	IF	Citations
1	Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MTâ€RNR1 Genotype. Clinical Pharmacology and Therapeutics, 2022, 111, 366-372.	4.7	50
2	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
3	Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data. Npj Genomic Medicine, 2022, 7, 12.	3.8	10
4	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers, 2022, 14, 2838.	3.7	1
5	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 1554.	3.7	9
6	MicroRNAs Targeting HIF-2Î±, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2Î± Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3099.	3.7	16
7	Circulating Levels of the Interferon-Î³-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy. Cancers, 2021, 13, 2849.	3.7	10
8	Sunitinib and Evofosfamide (<scp>TH</scp>-302) in Systemic Treatment-NaÃ¯ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <scp>GETNE</scp>-1408 Trial. Oncologist, 2021, 26, 941-949.	3.7	12
9	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. Cancers, 2021, 13, 4758.	3.7	14
10	Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. Genetics in Medicine, 2021, 23, 698-704.	2.4	9
11	Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. Pharmacogenomics Journal, 2020, 20, 179-191.	2.0	7
12	Hsaâ€•miRâ€•139â€•5p is a prognostic thyroid cancer marker involved in HNRNPFâ€•mediated alternative splicing. International Journal of Cancer, 2020, 146, 521-530.	5.1	29
13	PTEN expression and mutations in TSC1 , TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. International Journal of Cancer, 2020, 146, 1435-1444.	5.1	14
14	Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. Cancers, 2020, 12, 16.	3.7	72
15	Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. Lung Cancer, 2020, 147, 106-114.	2.0	5
16	Novel DNMT3A Germline Variant in a Patient with Multiple Paragangliomas and Papillary Thyroid Carcinoma. Cancers, 2020, 12, 3304.	3.7	5
17	A Novel Approach for the Identification of Pharmacogenetic Variants in MT-RNR1 through Next-Generation Sequencing Off-Target Data. Journal of Clinical Medicine, 2020, 9, 2082.	2.4	0
18	CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3548-3561.	3.6	5

#	Article	IF	Citations
19	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809.	2.5	5
20	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
21	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
22	Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Modern Pathology, 2020, 33, 2580-2590.	5.5	29
23	MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 640.e23-640.e29.	1.6	2
24	Pâ€€Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. Clinical Pharmacology and Therapeutics, 2020, 108, 671-680.	4.7	20
25	Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates. Biomedicines, 2020, 8, 94.	3.2	57
26	Overexpression of miRâ€483â€5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma/paraganglioma. Clinical and Translational Medicine, 2020, 10, e260.	4.0	4
27	Title is missing!. , 2020, 15, e0238809.		0
28	Title is missing!. , 2020, 15, e0238809.		0
29	Title is missing!. , 2020, 15, e0238809.		0
30	Title is missing!. , 2020, 15, e0238809.		0
31	The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. Whatâ€™s next? An urgent clinical unmet need for patients. Drug Metabolism and Drug Interactions, 2020, 35, .	0.3	0
32	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
33	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. Theranostics, 2019, 9, 4946-4958.	10.0	54
34	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. American Journal of Human Genetics, 2019, 104, 651-664.	6.2	51
35	A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer. Oncologist, 2019, 24, e1024-e1033.	3.7	16
36	Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy. Oncologist, 2019, 24, e784-e792.	3.7	20

#	Article	IF	Citations
37	Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.. Journal of Clinical Oncology, 2019, 37, TPS503-TPS503.	1.6	3
38	A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2350-2356.	7.0	7
39	Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 352-358.	4.9	18
40	Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients. Pharmacogenetics and Genomics, 2018, 28, 41-48.	1.5	13
41	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
42	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genetics in Medicine, 2018, 20, 622-629.	2.4	66
43	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews, 2018, 70, 209-222.	7.7	12
44	Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation. BMC Cancer, 2018, 18, 561.	2.6	13
45	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
46	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
47	Gain-of-function mutations in DNMT3A in patients with paraganglioma. Genetics in Medicine, 2018, 20, 1644-1651.	2.4	73
48	Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics Journal, 2017, 17, 42-46.	2.0	21
49	Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancerâ€"GEnetic- and tumor-related biomarkers for response and toxicity. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 529.e9-529.e16.	1.6	9
50	Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. Pharmacogenetics and Genomics, 2017, 27, 227-231.	1.5	5
51	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
52	mTOR Pathway Mutations and Response to Rapalogs in RCCâ€"Letter. Clinical Cancer Research, 2017, 23, 5320-5320.	7.0	3
53	Association between SLC19A1 gene polymorphism and high dose methotrexate toxicity in childhood acute lymphoblastic leukaemia and non Hodgkin malignant lymphoma: introducing a haplotype based approach. Radiology and Oncology, 2017, 51, 455-462.	1.7	14
54	Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR -Activating Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1310-1315.	4.9	16

#	Article	IF	Citations
55	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
56	Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer, 2017, 17, 63.	2.6	25
57	Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2017, 23, 1227-1235.	7.0	16
58	A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01). European Urology Focus, 2017, 3, 430-436.	3.1	4
59	Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE, 2017, 12, e0180192.	2.5	27
60	Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. Oncotarget, 2017, 8, 1204-1212.	1.8	6
61	SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. Pharmacogenomics, 2016, 17, 463-471.	1.3	8
62	The role of pharmacogenetics and pharmacogenomics in 21st-century medicine: state of the art and new challenges discussed in the VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics Society (SEFF). Drug Metabolism and Personalized Therapy, 2016, 31, 1-2.	0.6	2
63	Progress in pharmacogenetics: consortiums and new strategies. Drug Metabolism and Personalized Therapy, 2016, 31, 17-23.	0.6	12
64	Human genetics: international projects and personalized medicine. Drug Metabolism and Personalized Therapy, 2016, 31, 3-8.	0.6	10
65	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight, 2016, 1, e86051.	5.0	39
66	Abstract P3-07-40: Pharmacogenetic study of exemestane and everolimus in metastatic breast cancer patients progressing on prior non-steroidal aromatase inhibitors. , 2016, , .		0
67	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxelâ€"Letter. Clinical Cancer Research, 2015, 21, 3092-3093.	7.0	9
68	Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. Breast Cancer Research and Treatment, 2015, 149, 385-394.	2.5	27
69	Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene. Journal of the National Cancer Institute, 2015, 107, .	6.3	143
70	Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of Oncology, 2015, 26, 1987-1993.	1.2	112
71	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British Journal of Cancer, 2015, 112, 1190-1198.	6.4	35
72	Functional and in silico assessment of MAX variants of unknown significance. Journal of Molecular Medicine, 2015, 93, 1247-1255.	3.9	25

#	Article	IF	Citations
73	CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. European Urology, 2015, 68, 621-629.	1.9	75
74	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research, 2015, 21, 3020-3030.	7.0	53
75	Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. Journal of Medical Genetics, 2015, 52, 647-656.	3.2	102
76	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics, 2015, 16, 929-937.	1.3	17
77	Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European Journal of Clinical Pharmacology, 2015, 71, 1477-1484.	1.9	19
78	Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. Clinical Cancer Research, 2015, 21, 322-328.	7.0	61
79	Pharmacogenomic biomarkers for personalized cancer treatment. Journal of Internal Medicine, 2015, 277, 201-217.	6.0	57
80	Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 179-186.	1.6	10
81	High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics Journal, 2015, 15, 288-292.	2.0	48
82	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
83	VEGF, VEGFR3, and PDGFRB Protein Expression Is Influenced by RAS Mutations in Medullary Thyroid Carcinoma. Thyroid, 2014, 24, 1251-1255.	4.5	18
84	Oxaliplatin induced-neuropathy in digestive tumors. Critical Reviews in Oncology/Hematology, 2014, 89, 166-178.	4.4	40
85	Differential Gene Expression of Medullary Thyroid Carcinoma Reveals Specific Markers Associated with Genetic Conditions. American Journal of Pathology, 2013, 182, 350-362.	3.8	35
86	Molecular Markers to Predict Response to Therapy. Seminars in Oncology, 2013, 40, 444-458.	2.2	18
87	Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Annals of Oncology, 2013, 24, 2409-2414.	1.2	73
88	Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics, 2013, 22, 2169-2176.	2.9	142
89	Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine-Related Cancer, 2013, 20, 477-493.	3.1	52
90	Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. Journal of Medical Genetics, 2013, 50, 599-605.	3.2	67

#	Article	IF	Citations
91	Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 611-619.	3.1	17
92	Regulatory Polymorphisms in Î²-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2012, 18, 4441-4448.	7.0	61
93	Hematologic Î²-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity. Cancer Research, 2012, 72, 4744-4752.	0.9	26
94	Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. Pharmacogenomics, 2012, 13, 1621-1633.	1.3	11
95	Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene, 2012, 506, 62-68.	2.2	15
96	Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. Pharmacogenomics, 2012, 13, 1583-1594.	1.3	27
97	Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene. PLoS ONE, 2012, 7, e38847.	2.5	71
98	Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 2011, 43, 663-667.	21.4	478
99	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncology, The, 2011, 12, 1143-1150.	10.7	217
100	Detection of the first gross CDC73 germline deletion in an HPTâ€JT syndrome family. Genes Chromosomes and Cancer, 2011, 50, 922-929.	2.8	41
101	Microtubule-targeting drugs and personalization of cancer treatment. Pharmacogenomics, 2011, 12, 449-451.	1.3	0
102	Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics Journal, 2011, 11, 121-129.	2.0	112
103	Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Human Genetics, 2010, 127, 1-17.	3.8	110
104	Tumoral and tissueâ€specific expression of the major human Î²â€tubulin isotypes. Cytoskeleton, 2010, 67, 214-223.	2.0	221
105	Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Molecular Endocrinology, 2010, 24, 2382-2391.	3.7	179
106	Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocrine-Related Cancer, 2010, 17, 7-16.	3.1	108
107	Allelic variant at â^'79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. Endocrine-Related Cancer, 2010, 17, 317-328.	3.1	35
108	Pharmacogenomics of paclitaxel. Pharmacogenomics, 2010, 11, 621-623.	1.3	43

#	Article	IF	Citations
109	The miR-200 family controls Â-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocrine-Related Cancer, 2010, 18, 85-95.	3.1	188
110	The hematopoietic-specific Î²1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle, 2009, 8, 3914-3924.	2.6	18
111	Genetics of Pheochromocytoma and Paraganglioma in Spanish Patients. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1701-1705.	3.6	120
112	Rationalization of Genetic Testing in Patients with Apparently Sporadic Pheochromocytoma/Paraganglioma. Hormone and Metabolic Research, 2009, 41, 672-675.	1.5	41
113	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. PLoS Genetics, 2009, 5, e1000637.	3.5	140
114	Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. European Journal of Human Genetics, 2009, 17, 991-998.	2.8	43
115	Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Analytical Biochemistry, 2009, 389, 74-76.	2.4	14
116	Cytochrome P450 2D6 Genotyping. CNS Drugs, 2009, 23, 181-191.	5.9	33
117	CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for costâ€“effectiveness studies. Pharmacogenomics, 2009, 10, 685-699.	1.3	34
118	SDHC mutation in an elderly patient without familial antecedents. Clinical Endocrinology, 2008, 69, 906-910.	2.4	37
119	Impact of genetic polymorphisms in CYP2C8 and rosiglitazone intake on the urinary excretion of dihydroxyeicosatrienoic acids. Pharmacogenomics, 2008, 9, 277-288.	1.3	22
120	Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics Journal, 2008, 8, 268-277.	2.0	59
121	Molecular characterisation of a common SDHB deletion in paraganglioma patients. Journal of Medical Genetics, 2007, 45, 233-238.	3.2	69
122	Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. Endocrine-Related Cancer, 2007, 14, 645-654.	3.1	34
123	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood, 2007, 110, 3345-3351.	1.4	42
124	Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Human Mutation, 2007, 28, 613-621.	2.5	41
125	Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, 116, 496-526.		990
126	Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochemical and Biophysical Research Communications, 2006, 341, 451-458.	2.1	98

#	Article	IF	Citations
127	Cytochrome P450 pharmacogenetics and cancer. Oncogene, 2006, 25, 1679-1691.	5.9	492
128	GrossSDHB deletions in patients with paraganglioma detected by multiplex PCR: A possible hot spot?. Genes Chromosomes and Cancer, 2006, 45, 213-219.	2.8	73
129	Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers. Clinical Pharmacology and Therapeutics, 2005, 77, 259-270.	4.7	52
130	Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1563-1570.	4.0	106
131	Transcriptional Regulation of the Human CYP2A6 Gene. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 814-822.	2.5	44
132	A Novel Polymorphic Cytochrome P450 Formed by Splicing of CYP3A7 and the Pseudogene CYP3AP1. Journal of Biological Chemistry, 2005, 280, 28324-28331.	3.4	22
133	Phenotypeâ€“genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochemical and Biophysical Research Communications, 2005, 338, 299-305.	2.1	93
134	Collaboration with other firms and customers: innovationâ€™s secret weapon. Strategy and Leadership, 2004, 32, 16-20.	0.5	24
135	A nicotineC-oxidase gene (CYP2A6) polymorphism important for promoter activity. Human Mutation, 2004, 23, 258-266.	2.5	32
136	Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics and Genomics, 2004, 14, 369-379.	5.7	28
137	Transcriptional Regulation of Human CYP3A4 Basal Expression by CCAAT Enhancer-Binding Protein Î± and Hepatocyte Nuclear Factor-3Î³. Molecular Pharmacology, 2003, 63, 1180-1189.	2.3	97
138	Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica, 2002, 32, 505-520.	1.1	340
139	Cytochrome P-450 mRNA Expression in Human Liver and Its Relationship with Enzyme Activity. Archives of Biochemistry and Biophysics, 2001, 393, 308-315.	3.0	129
140	Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. FEBS Journal, 2001, 268, 1448-1459.	0.2	62
141	Quantitative RT-PCR Measurement of Human Cytochrome P-450s: Application to Drug Induction Studies. Archives of Biochemistry and Biophysics, 2000, 376, 109-116.	3.0	93
142	Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. , 1998, 177, 553-562.		125